Leishmaniasis

SUDAN

2014

Country General Information (WHO, 2013)

|			
Total population:	37,964,000	Age group <15/>14 years, %:	41% / 59%
Gender (%, F/M):	49.8% / 50.2%	Life expectancy at birth in years (F/M):	65 / 61
GDP (PPP int $):	2370	Number of 2nd sub-national administrative level divisions, name:	176, Locality
Income status:	Lower middle		

Epidemiology

|	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Endemic
Number of new cases (incidence):	3415	1053	52	0
Number of relapse cases:	105	No data	N/A	0
Total number of cases:	3520	1053	52	0
Imported cases (n, %):	11 0.3%	No data	No data	No data
Gender distribution (% F):[a]	29%	24%	No data	N/A
Age group distribution (%, <5/5-14/>14):[a]	(19/26/55)	(28/24/48)	(15/23/62)	N/A
Incidence rate (cases/10 000 population in endemic areas):[b]	11.05	7.18	N/A	N/A
Number of endemic 2nd sub-national administrative level divisions (n):	13	4	N/A	N/A
Population at risk[1] (%, n/total):[b]	9% (3090126/ 34470138)	4% (1465592/ 34470138)	N/A	N/A
Was there any outbreak?	No	Yes	N/A	N/A
Number of new[2] foci:	2	1	N/A	N/A

N/A = not applicable   VL = visceral leishmaniasis   CL = cutaneous leishmaniasis   PKDL = post-kala-azar dermal leishmaniasis   MCL = mucocutaneous leishmaniasis

Monthly distribution of **new cases,** January-December

2014	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	264	252	263	281	305	248	268	230	238	299	387	380
CL	97	115	98	74	77	66	80	88	106	73	79	100

Number of new CL cases reported by month in 2013 and 2014

Number of new (primary) VL cases reported by month in 2013 and 2014

Indicence rate/10 000 population and number of new CL (left) and new (primary) VL (right) cases from 1998 to 2014

Number of cases and incidence rate[3] of CL*

Number of cases and incidence rate[3] of VL

* No data available

[a] Sociodemographic information was provided for new cases

[b] Incidence and population at risk were calculated with population census figures in 2008

[1] Defined as "Number of people living in 3rd sub-national administrative level endemic areas"

[2] For this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever

[3] Incidence rate at the national level

Distribution of new CL (left) and new (primary) VL (right) cases

No data under national level

Control and surveillance

Year Leishmaniasis National Control Programme (LNCP) was established:	2004	Year latest national guidelines were published:	2014
Type of surveillance:	Vertical	Is leishmaniasis a notifiable disease (mandatory reporting)?	Yes
Is there a vector control programme?	Yes	Is there a reservoir host control programme?	No
Type of insecticide used for IRS:	bendiocarb/pyrethroid	Number of leishmaniasis health facilities:	25

Diagnosis

	VL	CL	PKDL	MCL
Number of people screened actively for:	No data	0	No data	No data
Number of people screened passively for:	No data	No data	No data	No data
VL cases diagnosed by RDT* (%, # RDT+/total VL cases):	59% (2011/3520)	N/A	N/A	N/A
Proportion of positive RDT* (%, # RDT+/total RDT):	16% (2011/12200)	N/A	N/A	N/A
Cases diagnosed by direct examination (parasitology) (%, # slides +/total cases):	15% (168/3520)	No data	N/A	N/A
Proportion of positive slides (%, # slides +/total slides):	79% (168/213)	No data	N/A	N/A
Cases diagnosed clinically (%, # clinical cases/total cases):	0% (0/3520)	N/A	N/A	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	No data	N/A

* These indicators apply only for new (primary) VL cases   VL = visceral leishmaniasis   PKDL = post-kala-azar dermal leishmaniasis

N/A = not applicable   RDT = rapid diagnostic test   HIV = human immunodeficiency virus   MCL = mucocutaneous leishmaniasis   CL = cutaneous leishmaniasis

Treatment and medicines

Is treatment provided free of charge in the public sector?	Yes
Antileishmanial medicines included in the national List of Essential Medicines:	Meglumine antimoniate, sodium stibogluconate (SSG), liposomal amphotericin B, amphotericin B deoxycholate, paromomycin, pentamidine

TREATMENT OUTCOME	VL	
Proportion of relapse cases:[4]	3%	(105/3520)
Initial cure rate:	49%	(1736/3520)
Failure[5] rate:	26%	(916/3520)
Case-fatality rate:	1%	(36/3520)

[4] A relapse case in this country is defined as: No definition available

[5] A failure case in this country is defined as: No definition available